Divani Caravel Hotel,
Athens, 8-11/03/2023

IASIS PHARMA participated in the 21st National Diabetes Congress, showing its active interest in Diabetes Mellitus disease, promoting cornerstone pharmaceutical products for type 2 diabetes. Moreover, IASIS PHARMA is about to invest significantly in T2DM in the near future, launching more than 4 original products.

The conference took place on March 8-11, 2023, at the Divani Caravel Hotel in Athens, with the participation of more than 2,000 Health Care Professionals.

The event is aimed at Pathologists, General Practitioners, Endocrinologists & Nephrologists. Also, it consists of a wide range of topics and is held in parallel halls.

IASIS PHARMA participated in the event with an exhibition stand, where experts had the opportunity to visit and learn about the range of high-quality proprietary pharmaceuticals available from the company.

IASIS PHARMA presented the following products:

• Rami – Amlo®
  Each hard capsule contains combination of Ramipril-Amlodipine, in the following strengths:
  5/5, 5/10, 10/5, 10/10 (mg/mg) x28.
• Rami – Amlo Plus®
  Each hard capsule contains a combination of Ramipril-Amlodipine-HCTZ, in the following strengths: 5/5/12,5, 5/5/25, 10/5/25, 10/10/25 (mg/mg/mg) x28.
• Glucofree®
  Each film-coated tablet contains 850 mg metformin hydrochloride, equivalent to 662,9 mg metformin respectively (box of 60 f.c. tabs).
• Glucoplus®
  Each film-coated tablet contains 1000 mg metformin hydrochloride, equivalent to 780 mg metformin respectively (box of 30 f.c. tabs & 60 f.c. tabs).
• MAG-IASIS®
  Effervescent tablets (tube of 40 tablets).
  Each tablet contains 1193,57 mg magnesium citrate and 667,56 mg magnesium aspartate dihydrate, which equal to 243 mg Magnesium (10mmol Magnesium).